Copyright
©The Author(s) 2024.
World J Diabetes. May 15, 2024; 15(5): 935-944
Published online May 15, 2024. doi: 10.4239/wjd.v15.i5.935
Published online May 15, 2024. doi: 10.4239/wjd.v15.i5.935
Figure 5 The prevalence of glutamic acid decarboxylase autoantibodies in 3 Screen Islet Cell Autoantibody-positive patients.
A: Autoimmune thyroid disease (AITD) with type 1 diabetes (T1D), B: AITD with type 2 diabetes (T2D), C: AITD without diabetes. Among the 3 Screen Islet Cell Autoantibody-positive patients, 12.5% of AITD patients with T1D, 20.0% of AITD patients with T2D, and 20.0% of those without diabetes were negative for glutamic acid decarboxylase autoantibody. AITD: Autoimmune thyroid disease.
- Citation: Kawasaki E, Tamai H, Fukuyama T, Sagara Y, Hidaka R, Uchida A, Tojikubo M, Tatsumoto N, Akehi Y, Hiromatsu Y. Enzyme-linked immunosorbent assay of 3 Screen Islet Cell Autoantibody in patients with autoimmune thyroid disease. World J Diabetes 2024; 15(5): 935-944
- URL: https://www.wjgnet.com/1948-9358/full/v15/i5/935.htm
- DOI: https://dx.doi.org/10.4239/wjd.v15.i5.935